Institutional Fund
Ecor1 Capital, LLC
San Francisco, CACIK 15871145 filings on record
Portfolio Value
$2.34B
Q1 2026
Holdings
29
Reported positions
New Buys
10
Opened this quarter
QoQ Change
+6.8%
from $2.19B
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Zymeworks Inc24.6%
- Anaptysbio Inc18.7%
- Jazz Pharmaceuticals PLC13.8%
- Centessa Pharmaceuticals PLC10.2%
- Crinetics Pharmaceuticals In6.7%
- Aktis Oncology Inc3.7%
- Other22.4%
Portfolio Holdings
29 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Zymeworks Inc | 22.97M | $575.18M | 24.6% | 0 | Held |
| 2 | Anaptysbio Inc | 7.88M | $437.03M | 18.7% | 0 | Held |
| 3 | Jazz Pharmaceuticals PLC | 1.71M | $322.61M | 13.8% | 0 | Held |
| 4 | Centessa Pharmaceuticals PLC | 6.00M | $238.32M | 10.2% | +2.88M | Added |
| 5 | Crinetics Pharmaceuticals In | 4.29M | $155.74M | 6.7% | 0 | Held |
| 6 | Aktis Oncology Inc | 4.82M | $86.31M | 3.7% | +4.82M | New |
| 7 | Oric Pharmaceuticals Inc | 6.73M | $85.25M | 3.6% | 0 | Held |
| 8 | Cg Oncology Inc | 1.10M | $74.58M | 3.2% | +330.0K | Added |
| 9 | Crispr Therapeutics AG | 1.39M | $66.09M | 2.8% | 0 | Held |
| 10 | Eton Pharmaceuticals Inc | 2.17M | $53.60M | 2.3% | +141.4K | Added |
19 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio